Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
$0.22
+0.1%		$0.20
$0.03
▼
$0.33
$35.33M0.2266,885 shs317,551 shs
Rafael Holdings, Inc. stock logo
RFL
Rafael
$2.39
+4.2%		$2.23
$1.12
▼
$3.96
$119.08M0.4119,023 shs182,359 shs
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$5.31
+3.7%		$5.28
$3.71
▼
$8.74
$142.62M1.79682,972 shs1.24 million shs
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
$1.25
-4.9%		$1.38
$0.92
▼
$1.92
$118.62M2.36231,492 shs254,272 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
+0.14%-2.48%+0.79%+348.65%+257.00%
Rafael Holdings, Inc. stock logo
RFL
Rafael
+3.83%-4.52%+22.03%+6.09%+77.47%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
+3.71%+0.19%+6.20%-26.76%+23.78%
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
-4.94%-10.07%-10.07%+13.64%+2.46%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
$0.22
+0.1%		$0.20
$0.03
▼
$0.33
$35.33M0.2266,885 shs317,551 shs
Rafael Holdings, Inc. stock logo
RFL
Rafael
$2.39
+4.2%		$2.23
$1.12
▼
$3.96
$119.08M0.4119,023 shs182,359 shs
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$5.31
+3.7%		$5.28
$3.71
▼
$8.74
$142.62M1.79682,972 shs1.24 million shs
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
$1.25
-4.9%		$1.38
$0.92
▼
$1.92
$118.62M2.36231,492 shs254,272 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
+0.14%-2.48%+0.79%+348.65%+257.00%
Rafael Holdings, Inc. stock logo
RFL
Rafael
+3.83%-4.52%+22.03%+6.09%+77.47%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
+3.71%+0.19%+6.20%-26.76%+23.78%
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
-4.94%-10.07%-10.07%+13.64%+2.46%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
0.00
N/AN/AN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
1.00
SellN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
2.57
Moderate Buy$18.75253.11% Upside
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
2.25
Hold$3.75200.00% Upside

Current Analyst Ratings Breakdown

Latest BETRF, UNCY, VANI, and RFL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/25/2026
Rafael Holdings, Inc. stock logo
RFL
Rafael
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/20/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSpeculative Buy$13.00 ➝ $15.00
8/19/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/13/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$37.00 ➝ $25.00
8/12/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$22.00 ➝ $20.00
7/21/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/7/2026
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/1/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetSpeculative Buy$18.00 ➝ $13.00
6/30/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$22.00
6/30/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$22.00 ➝ $15.00
(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
N/AN/AN/AN/A($0.03) per shareN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
$920K134.92N/AN/A$1.91 per share1.25
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$680K217.48N/AN/A$1.41 per share3.77
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
N/AN/AN/AN/A$0.20 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
-$1.07MN/AN/AN/AN/AN/AN/A-772.34%N/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
-$30.52M-$0.68N/AN/AN/A-3,321.74%-41.27%-35.32%10/28/2026 (Estimated)
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$26.56M-$1.75N/A2.46N/AN/A-91.50%-61.47%11/11/2026 (Estimated)
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
-$26.61M-$0.35N/AN/AN/AN/A-191.05%-70.91%11/12/2026 (Estimated)

Latest BETRF, UNCY, VANI, and RFL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
-$0.0833-$0.07+$0.0133-$0.07N/AN/A
8/12/2026Q2 2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$0.4710-$0.06+$0.4110-$0.06$22.22 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
N/AN/AN/AN/AN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
N/AN/AN/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/AN/AN/AN/AN/A
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
N/A
0.04
0.04
Rafael Holdings, Inc. stock logo
RFL
Rafael
N/A
3.16
3.14
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/A
3.81
3.81
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
N/A
3.25
3.25

Institutional Ownership

CompanyInstitutional Ownership
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
0.01%
Rafael Holdings, Inc. stock logo
RFL
Rafael
11.30%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
40.42%
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
6.78%

Insider Ownership

CompanyInsider Ownership
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
34.77%
Rafael Holdings, Inc. stock logo
RFL
Rafael
32.90%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
6.03%
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
53.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
7163.25 million106.49 millionNot Optionable
Rafael Holdings, Inc. stock logo
RFL
Rafael
2052.00 million34.89 millionOptionable
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
927.85 million26.18 millionNot Optionable
Vivani Medical, Inc. stock logo
VANI
Vivani Medical
2090.20 million42.13 millionOptionable

Recent News About These Companies

Vivani Medical (NASDAQ:VANI) Trading Down 9.1% - Time to Sell?
September 9 at 2:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31011930
Vivani Medical (NASDAQ:VANI) Trading Down 9.1% - Here's What Happened
September 9 at 2:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vivani-medical-nasdaq-vani-trading-down-91-heres-what-happened-2026-09-09/
Vivani Medical to Participate in Upcoming Lake Street and H.C. Wainwright Investor Conferences
September 3, 2026  |  quiverquant.comQ
Vivani Medical Announces Participation in Upcoming Investor Conferences
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3356268/0/en/vivani-medical-announces-participation-in-upcoming-investor-conferences.html
Analysts Offer Insights on Healthcare Companies: Vivani Medical (VANI) and InspireMD (NSPR)
August 20, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NSPR/pressreleases/3930659/analysts-offer-insights-on-healthcare-companies-vivani-medical-vani-and-inspiremd-nspr/
Vivani Medical Inc U5P
August 19, 2026  |  morningstar.comM
Vivani Medical Updates Investors with Regulation FD Presentation
August 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/vivani-medical-updates-investors-with-regulation-fd-presentation?utm_source=marketbeat.com&utm_medium=referral
Wall Street Zen Upgrades Vivani Medical (NASDAQ:VANI) to "Hold"
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-vivani-medical-nasdaqvani-to-hold-2026-08-15/
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vivani-medical-reports-second-quarter-200500168.html
Vivani Medical (NASDAQ:VANI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vivani-medical-nasdaqvani-releases-quarterly-earnings-results-beats-estimates-by-001-eps-2026-08-13/
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344932/0/en/vivani-medical-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Vivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vivani-medical-completes-enrollment-dosing-150007366.html
ClearOne (CLRO) stock soars over 98% after hours: Here's what you need to know
August 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/clearone-clro-stock-soars-over-98-after-hours-here-s-what-you-need-to-know/ar-AA29vdAl
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic ...
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vivani-medical-announces-successful-dosing-120000198.html
Vivani Completes Enrollment in SLIM-1 Semaglutide Implant Trial
August 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/vivani-completes-enrollment-in-slim-1-semaglutide-implant-trial?utm_source=marketbeat.com&utm_medium=referral
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
July 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/14/3327241/0/en/vivani-medical-to-present-at-the-emerging-growth-conference-on-july-15-2026.html
Next Frontier In Weight Loss? New Implant Looks To Lock In GLP-1 Results
July 14, 2026  |  msn.comhttps://www.msn.com/en-in/health/other/next-frontier-in-weight-loss-new-implant-looks-to-lock-in-glp-1-results/ar-AA27Qwhm
The next GLP-1 bet? Implant draws Novo interest
July 13, 2026  |  beckershospitalreview.comB
Vivani Medical
July 13, 2026  |  fool.comhttps://www.fool.com/quote/nasdaq/vani/
Weight-loss implant could one day replace Ozempic injections
July 12, 2026  |  msn.comhttps://www.msn.com/en-us/health/weightloss/weight-loss-implant-could-one-day-replace-ozempic-injections/ar-AA27Krdd
Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal
July 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-nordisk-cpse-novo-b-161205528.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

BetterLife Pharma stock logo

BetterLife Pharma OTCMKTS:BETRF

$0.22 +0.00 (+0.14%)
As of 09/10/2026 03:47 PM Eastern

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Rafael stock logo

Rafael NYSE:RFL

$2.39 +0.10 (+4.24%)
Closing price 09/10/2026 03:59 PM Eastern
Extended Trading
$2.36 -0.03 (-1.34%)
As of 09/10/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Unicycive Therapeutics stock logo

Unicycive Therapeutics NASDAQ:UNCY

$5.31 +0.19 (+3.71%)
Closing price 09/10/2026 04:00 PM Eastern
Extended Trading
$5.36 +0.05 (+0.85%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Vivani Medical stock logo

Vivani Medical NASDAQ:VANI

$1.25 -0.07 (-4.94%)
Closing price 09/10/2026 04:00 PM Eastern
Extended Trading
$1.31 +0.06 (+4.96%)
As of 07:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas